Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Zymeworks Inc.

< Previous 1 2 3 4 Next >
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Tickers ZYME
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback